Evidence map›Paper›PMID 40668643›Full record

Trial reportDiabetes2025

Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate: A Randomized Trial.

Siham Abdelgani, Ahmed Khattab, John M Adams, Fahd Al-Mulla, Mohamed Abu-Farha, Gozde Baskoy, Jehad Abubaker, Aurora Merovci, Ralph A DeFronzo, Renata Belfort De Aguiar and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Siham AbdelganiDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.
Ahmed KhattabDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.
John M AdamsDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.
Fahd Al-MullaTranslational Research Department, Dasman Diabetes Institute, Dasman, Kuwait.
Mohamed Abu-FarhaTranslational Research Department, Dasman Diabetes Institute, Dasman, Kuwait.
Gozde BaskoyDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.
Jehad AbubakerTranslational Research Department, Dasman Diabetes Institute, Dasman, Kuwait.
Aurora MerovciDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.
Ralph A DeFronzoDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.
Renata Belfort De AguiarDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.
Muhammad Abdul-GhaniDivision of Diabetes, University of Texas Health Science Center, San Antonio, TX.ORCID 0000-0003-4556-1787

Funding

The Role of Glucose Mediated Glucose Uptake in the pathogenesis of IFG and IGTR01DK097554 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Muhammad Abdul-Ghani · 2012 to 2026
$6.7M
NIDDK NIH HHS R01 DK097554NIH HHS 2R01DK097554-06
6 · The paper itself

Abstract

article highlightsSodium-glucose cotransporter 2 inhibitors (SGLT2i) cause an increase in hepatic glucose production (HGP). We previously showed that SGLT2i cause a rapid (within 4 h) increase in the total-body norepinephrine (NE) turnover rate, which could explain the increase in HGP. Because the increase in HGP caused by SGLT2i is long-lasting, we examined the long-term effect of SGLT2i on the NE turnover rate. Empagliflozin caused a decrease in total-body NE turnover at 1 day and at 12 weeks after starting therapy, despite an increase in glucose production, and the magnitude of decrease in NE turnover inversely correlated with the increase in HGP caused by empagliflozin.

Indexed as

Benzhydryl CompoundsDiabetes Mellitus, Type 2GlucoseGlucosidesNorepinephrineSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansLiverMaleMiddle AgedBenzhydryl CompoundsempagliflozinGlucoseGlucosidesNorepinephrineSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID40668643
PMCPMC12365416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.